Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 16:15 ET
|
Unicycive Therapeutics, Inc.
Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. ...
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023 07:05 ET
|
ZyVersa Therapeutics
Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
October 23, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023 07:05 ET
|
ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.
Rising Incidence of Kidney Disorders Boosts Kidney Disease Market: Over 37 Million Americans Affected, Highlighting Growing Demand for Treatment Solutions
October 12, 2023 07:13 ET
|
Research and Markets
Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "Kidney Disease Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global kidney diseases market is...
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
October 06, 2023 11:28 ET
|
American Kidney Fund
ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate...
American Kidney Fund Launches Educational Awareness Campaigns for Two Rare Kidney Diseases
September 26, 2023 09:18 ET
|
American Kidney Fund
ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched educational awareness campaigns for two rare kidney diseases: complement 3 glomerulopathy (C3G) and...
American Kidney Fund, Home Dialyzors United Partner to Host Second Annual Dialysis at Home Summit
September 12, 2023 10:24 ET
|
American Kidney Fund
ROCKVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has partnered with Home Dialyzors United, a nonprofit advocating on behalf of the home dialyzor community, to host...
Travere Therapeutics Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
September 08, 2023 09:51 ET
|
American Kidney Fund
ROCKVILLE, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Travere Therapeutics has joined the 2023 class in AKF’s Corporate Membership Program as a...
Amgen Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
September 06, 2023 09:10 ET
|
American Kidney Fund
ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today expressed its appreciation for Amgen’s participation in the 2023 class of its Corporate Membership Program as...